Found 6617 of ic50 for PROTEIN ARGININE N-METHYLTRANSFERASE 5
having polymerids = 9391 and
complexids = 179,68
having polymerids = 9391 and
complexids = 179,68
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.130nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.130nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.140nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5 expressed in Sf9 insect cells using histone H2A as peptide after 120 mins in presence of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.160nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <0.200nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.210nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.240nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.25nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.290nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.310nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.320nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.330nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.330nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.350nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.360nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.420nMAssay Description:Inhibition of human PRMT5 by fluorescence-based SAHH-coupled assayMore data for this Ligand-Target Pair
Ligand Info
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.440nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.470nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Csir-Indian Institute Of Chemical Biology
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair